A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Excluded: TP53 mutation

Have high-risk CLL TP53 mutations and 17P deletion.

Excluded: TP53 17P deletion

Have high-risk CLL TP53 mutations and 17P deletion.

Must have received: Bruton tyrosine kinase inhibitor (zanubrutinib) — Cohort 1: at least 12 months; Cohort 2: any duration

Must be actively taking zanubrutinib for at least 12 months (Cohort 1); Must be actively taking zanubrutinib (Cohort 2); Participants must have had direct progression on zanubrutinib (within 3 months prior to study entry; administered as monotherapy or in combination) and no other anticancer therapy administered since (Cohort 2)

Cannot have received: CAR-T cell therapy

Received prior chimeric antigen receptor-T cell therapy.

Cannot have received: investigational drug

Received prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, prior to C1D1

Cannot have received: allogeneic hematopoietic stem cell transplant

allogeneic hematopoietic stem cell transplant (HSCT) within 60 days prior to C1D1

Cannot have received: systemic anticancer therapy

Exception: zanubrutinib may be continued until the day before C1D1

Any prior systemic anticancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 21 days or 5 half-lives, whichever is shorter, prior to C1D1 (with the exception of zanubrutinib, which may be continued until the day before C1D1).